m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT03063
 [1]
m6A modification HOTAIR HOTAIR METTL14 Methylation : m6A sites Indirect Enhancement Histone modification H3K4me1 LSD1 PPP1CA
m6A Modification:
m6A Regulator Methyltransferase-like 14 (METTL14) WRITER
 Regulator Info 
m6A Target HOX transcript antisense RNA (HOTAIR)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Histone modification (HistMod)
Epigenetic Regulator Lysine-specific histone demethylase 1A (KDM1A) ERASER View Details
Regulated Target Histone H3 lysine 4 monomethylation (H3K4me1) View Details
Downstream Gene PPP1CA View Details
Crosstalk Relationship m6A  →  Histone modification Enhancement
Crosstalk Mechanism m6A modification indirectly regulates histone modification through downstream signaling pathways
Crosstalk Summary METTL14-mediated upregulation of HOX transcript antisense RNA (HOTAIR) resulted in the repression of PPP1CA, which in turn facilitated the recruitment of KDM1A, thus catalyzing Histone H3 lysine 4 monomethylation (H3K4me1) demethylation and promoting oxycodone addiction.
Responsed Disease Disorders due to use of opioids ICD-11: 6C43.1
 Disease Info 
Responsed Drug MM-102
 Drug Info 
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
Lysine-specific histone demethylase 1A (KDM1A) 81 Compound(s) Regulating the Target Click to Show/Hide the Full List
 Compound Name IMG-7289 Phase 2 [2]
Synonyms
KQKBMHGOHXOHTD-KKUQBAQOSA-N; UNII-Y2T4ALDEAT; Y2T4ALDEAT; SCHEMBL17984236; Benzamide, N-((1S)-4-(((1R,2S)-2-(4-fluorophenyl)cyclopropyl)amino)-1-((4-methyl-1-piperazinyl)carbonyl)butyl)-4-(1H-1,2,3-triazol-1-yl)-; 1990504-34-1; N-[(2S)-1-(4-(methyl)piperazin-1-yl)-5-[[(1R,2S)-2-(4-fluorophenyl)-cyclopropyl]amino]-1-oxopentan-2-yl]-4-(1H-1,2,3-triazol-1-yl)benzamide
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 122460381
TTD: D03EOZ
DrugBank: DB15126
 Compound Name Vafidemstat Phase 2 [3]
Synonyms
(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 66714983
TTD: D5NAL9
 Compound Name CC-90011 Phase 2 [4]
Synonyms
UNII-W6F4FRQ5QC; W6F4FRQ5QC; CC90011; 1821307-10-1; CC-90011 besylate; 4-[2-(4-aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl]-2-fluorobenzonitrile; Pulrodemstat; 4-(2-(4-Aminopiperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; Pulrodemstat [INN]; CC-90011 Free base; SCHEMBL17222702; GTPL11284; US10023543, Example 7; BDBM283216; US10023543, Example 85; US10023543, Example 86; NSC822744; NSC-822744; compound 11 [PMID: 33034194]; Q67009340; NC1CCN(CC1)C=1N(C(C(=C(N1)C1=CC(=C(C#N)C=C1)F)C1=CC(=C(C=C1)OC)F)=O)C; 4-(2-(4-Amino-piperidin-1-yl)-5-(3-fluoro-4-methoxyphenyl)-1-methyl-6-oxo-1,6-dihydropyrimidin-4-yl)-2-fluorobenzonitrile; 4-[2-(4-amino-piperidin-1-yl)-5- (3-fluoro-4-methoxy-phenyl)-1- methyl-6-oxo-1,6-dihydro- pyrimidin-4-yl]-2-fluoro- benzonitrile; Benzonitrile, 4-(2-(4-amino-1-piperidinyl)-5-(3-fluoro-4-methoxyphenyl)-1,6-dihydro-1-methyl-6-oxo-4-pyrimidinyl)-2-fluoro-; V0Y
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 118483201
TTD: DB5UA2
 Compound Name ORY-2001 Phase 2 [5]
Synonyms
(1R,2S)-2-(4-(Benzyloxy)phenyl)-N-((5-imino-4,5-dihydro-1,3,4-oxadiazol-2-yl)methyl)cyclopropanamine; 1,3,4-Oxadiazole-2-methanamine, 4,5-dihydro-5-imino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1,3,4-Oxadiazole-2-methanamine, 5-amino-N-((1R,2S)-2-(4-(phenylmethoxy)phenyl)cyclopropyl)-; 1357362-02-7; 5-((((1R,2S)-2-(4-(benzyloxy)phenyl)cyclopropyl)amino)methyl)-1,3,4-oxadiazol-2-amine; 5-(((trans)-2-(4-(benzyloxy)phenyl)cyclopropylamino)methyl)-1,3,4-oxadiazol-2-amine; 5-[[[(1R,2S)-2-(4-phenylmethoxyphenyl)cyclopropyl]amino]methyl]-1,3,4-oxadiazol-2-amine; A930244; AKOS040742807; BCP29383; BDBM50594947; CHEMBL4802155; CS-0058593; HY-112623; LZ82JLT4UP; MS-25100; ORY 2001; ORY2001; ORY-2001; ORY-2001; SCHEMBL528204; UNII-LZ82JLT4UP; Vafidemstat; Vafidemstat [INN]; XBBRLCXCBCZIOI-DLBZAZTESA-N
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 66714983
TTD: DL50ZE
 Compound Name INCB59872 Phase 1/2 [2]
MOA Inhibitor
External Link
TTD: D0R7CD
 Compound Name CC-90011 Phase 1 [2]
MOA Inhibitor
External Link
TTD: D04GNG
 Compound Name GSK2879552 Phase 1 [6]
MOA Inhibitor
Activity IC50 = 24 nM
External Link
CID: 66571643
TTD: D0I4ZN
 Compound Name Seclidemstat Phase 1 [7]
Synonyms
UNII-TYH386V3WJ; SP-2577; TYH386V3WJ; 1423715-37-0; SP2577; CHEMBL4297641; SCHEMBL14697017; SCHEMBL14697019; EX-A3574; s6722; BS-15371; HY-103713; CS-0039281; Benzoic acid, 3-((4-methyl-1-piperazinyl)sulfonyl)-, (2E)-2-(1-(5-chloro-2-hydroxyphenyl)ethylidene)hydrazide
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 135565033
TTD: DCWT40
 Compound Name TAS-1440 Phase 1 [8]
MOA Inhibitor
External Link
TTD: DI17KH
 Compound Name PMID27019002-Compound-16 Patented [9]
MOA Inhibitor
Activity IC50 = 2220 nM
External Link
TTD: D02YGX
 Compound Name PMID27019002-Compound-41 Patented [9]
MOA Inhibitor
Activity IC50 = 19 nM
External Link
TTD: D05FVW
 Compound Name Benzenamine derivative 2 Patented [9]
Synonyms
PMID27019002-Compound-35
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D05HBM
 Compound Name PMID27019002-Compound-28a Patented [9]
MOA Inhibitor
Activity IC50 < 1000 nM
External Link
TTD: D06XEU
 Compound Name Aryl cyclopropylamine derivative 5 Patented [9]
Synonyms
PMID27019002-Compound-25c
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 352000 nM
External Link
TTD: D07IAO
 Compound Name Pyrimidine derivative 17 Patented [9]
Synonyms
PMID27019002-Compound-39
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 100 nM
External Link
TTD: D07LKA
 Compound Name PMID27019002-Compound-31b Patented [9]
MOA Inhibitor
Activity IC50 = 31380 nM
External Link
TTD: D08FVR
 Compound Name Benzenamine derivative 3 Patented [9]
Synonyms
PMID27019002-Compound-35a
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D08WMK
 Compound Name Cyclopropylamine derivative 1 Patented [9]
Synonyms
PMID27019002-Compound-23
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1 to 100 nM
External Link
TTD: D0B6GK
 Compound Name N6-cyclopropyllydine derivative 1 Patented [9]
Synonyms
PMID27019002-Compound-30
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 10 to 1000 nM
External Link
TTD: D0BE4Z
 Compound Name Tarnylcypromine derivative 1 Patented [9]
Synonyms
PMID27019002-Compound-18
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 1300 nM
External Link
TTD: D0BG7B
 Compound Name Cyclopropylamine derivative 7 Patented [9]
Synonyms
PMID27019002-Compound-29e
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0C0PK
 Compound Name Aryl cyclopropylamine derivative 4 Patented [9]
Synonyms
PMID27019002-Compound-25b
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 456000 nM
External Link
TTD: D0C1TH
 Compound Name PMID27019002-Compound-45 Patented [9]
MOA Inhibitor
External Link
TTD: D0D9CK
 Compound Name PMID27019002-Compound-13 Patented [9]
MOA Inhibitor
Activity IC50 = 5270 nM
External Link
TTD: D0DD4I
 Compound Name PMID27019002-Compound-49 Patented [9]
MOA Inhibitor
External Link
TTD: D0DL5J
 Compound Name Cyclopropylamine derivative 4 Patented [9]
Synonyms
PMID27019002-Compound-29b
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0F1CT
 Compound Name PMID27019002-Compound-42b Patented [9]
MOA Inhibitor
Activity IC50 > 3000 nM
External Link
TTD: D0GA7D
 Compound Name PMID27019002-Compound-31a Patented [9]
MOA Inhibitor
Activity IC50 = 39380 nM
External Link
TTD: D0I9QC
 Compound Name PMID27019002-Compound-43c Patented [9]
MOA Inhibitor
Activity IC50 = 81 nM
External Link
TTD: D0J1HQ
 Compound Name Aryl cyclopropylamine derivative 3 Patented [9]
Synonyms
PMID27019002-Compound-25a
    Click to Show/Hide
MOA Inhibitor
Activity Ki = 173000 nM
External Link
TTD: D0JE6I
 Compound Name Benzenamine derivative 4 Patented [9]
Synonyms
PMID27019002-Compound-36
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0KR0I
 Compound Name Cyclopropylamine derivative 6 Patented [9]
Synonyms
PMID27019002-Compound-29d
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0KZ5T
 Compound Name Pyrimidine derivative 16 Patented [9]
Synonyms
PMID27019002-Compound-38
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0L0DT
 Compound Name PMID27019002-Compound-28 Patented [9]
MOA Inhibitor
Activity IC50 < 1000 nM
External Link
TTD: D0L4OH
 Compound Name Heteroaryl-cyclopropylamine derivative 2 Patented [9]
Synonyms
PMID27019002-Compound-22a
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 to 1000 nM
External Link
TTD: D0LK8A
 Compound Name Cyclopropylamine derivative 5 Patented [9]
Synonyms
PMID27019002-Compound-29c
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0LR6D
 Compound Name PMID27019002-Compound-43b Patented [9]
MOA Inhibitor
Activity IC50 = 273 nM
External Link
TTD: D0MO5Y
 Compound Name Pyrimidine derivative 18 Patented [9]
Synonyms
PMID27019002-Compound-40
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0N2QZ
 Compound Name Cyclopropylamine derivative 3 Patented [9]
Synonyms
PMID27019002-Compound-29a
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0NJ6B
 Compound Name PMID27019002-Compound-20b Patented [9]
MOA Inhibitor
Activity IC50 = 1 to 100 nM
External Link
TTD: D0O2WW
 Compound Name PMID27019002-Compound-50 Patented [9]
MOA Inhibitor
External Link
TTD: D0P4NF
 Compound Name Cyclopropylamine derivative 8 Patented [9]
Synonyms
PMID27019002-Compound-32
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 to 500 nM
External Link
TTD: D0R7RY
 Compound Name PMID27019002-Compound-43a Patented [9]
MOA Inhibitor
Activity IC50 = 90 nM
External Link
TTD: D0RC0G
 Compound Name Benzenamine derivative 1 Patented [9]
Synonyms
PMID27019002-Compound-14
    Click to Show/Hide
MOA Inhibitor
External Link
TTD: D0U1DY
 Compound Name PMID27019002-Compound-7 Patented [9]
MOA Inhibitor
Activity IC50 = 59 nM
External Link
TTD: D0U4DT
 Compound Name PMID27019002-Compound-42a Patented [9]
MOA Inhibitor
Activity IC50 > 3000 nM
External Link
TTD: D0UG5Q
 Compound Name PMID27019002-Compound-37a Patented [9]
MOA Inhibitor
Activity IC50 = 11160 nM
External Link
TTD: D0VB7F
 Compound Name PMID27019002-Compound-44 Patented [9]
MOA Inhibitor
Activity IC50 = 1190 nM
External Link
TTD: D0W8XM
 Compound Name PMID27019002-Compound-21a Patented [9]
MOA Inhibitor
Activity IC50 = 100 nM
External Link
TTD: D0YI0V
 Compound Name PMID27019002-Compound-37b Patented [9]
MOA Inhibitor
Activity IC50 = 10540 nM
External Link
TTD: D0YX4R
 Compound Name Heteroaryl-cyclopropylamine derivative 4 Patented [9]
Synonyms
PMID27019002-Compound-22c
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 nM
External Link
TTD: D01CIK
 Compound Name Cyclopropylamine derivative 11 Patented [9]
Synonyms
PMID27019002-Compound-33c
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 180 nM
External Link
TTD: D02CIX
 Compound Name PMID25399762-Compound-Table 6-11 Patented [10]
MOA Inhibitor
Activity IC50 < 200 nM
External Link
TTD: D02WXS
 Compound Name PMID27019002-Compound-20a Patented [9]
MOA Inhibitor
Activity IC50 = 1 to 100 nM
External Link
TTD: D03MPD
 Compound Name Cyclopropylamine derivative 9 Patented [9]
Synonyms
PMID27019002-Compound-33a
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 230 nM
External Link
TTD: D04PWX
 Compound Name PMID25399762-Compound-Table 6-13 Patented [10]
MOA Inhibitor
Activity IC50 < 30 nM
External Link
TTD: D06KBT
 Compound Name Heteroaryl-cyclopropylamine derivative 3 Patented [9]
Synonyms
PMID27019002-Compound-22b
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 100 nM
External Link
TTD: D06VMN
 Compound Name Cyclopropylamine derivative 13 Patented [9]
Synonyms
PMID27019002-Compound-33e
    Click to Show/Hide
MOA Inhibitor
Activity IC50 < 100 nM
External Link
TTD: D07DIJ
 Compound Name PMID27019002-Compound-21b Patented [9]
MOA Inhibitor
Activity IC50 = 1 to 100 nM
External Link
TTD: D07MQD
 Compound Name PMID27019002-Compound-48 Patented [9]
MOA Inhibitor
External Link
TTD: D09OMM
 Compound Name PMID25399762-Compound-Table 6-10 Patented [10]
MOA Inhibitor
Activity IC50 < 100 nM
External Link
TTD: D0AI6J
 Compound Name PMID25399762-Compound-Table 6-12 Patented [10]
MOA Inhibitor
Activity IC50 < 200 nM
External Link
TTD: D0E7SF
 Compound Name PMID25399762-Compound-Table 6-9 Patented [10]
MOA Inhibitor
Activity IC50 < 20 nM
External Link
TTD: D0IO2A
 Compound Name PMID25399762-Compound-Table 6-14 Patented [10]
MOA Inhibitor
Activity IC50 < 100 nM
External Link
TTD: D0PM2S
 Compound Name PMID25399762-Compound-Table 6-15 Patented [10]
MOA Inhibitor
Activity IC50 < 50 nM
External Link
TTD: D0Q1EG
 Compound Name Cyclopropylamine derivative 12 Patented [9]
Synonyms
PMID27019002-Compound-33d
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 210 nM
External Link
TTD: D0R2YA
 Compound Name PMID27019002-Compound-21c Patented [9]
MOA Inhibitor
Activity IC50 = 1 to 100 nM
External Link
TTD: D0UE4K
 Compound Name Cyclopropylamine derivative 10 Patented [9]
Synonyms
PMID27019002-Compound-33b
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 240 nM
External Link
TTD: D0W9VF
 Compound Name PMID27019002-Compound-47 Patented [9]
MOA Inhibitor
External Link
TTD: D0WO5W
 Compound Name PMID27019002-Compound-17 Patented [9]
MOA Inhibitor
Activity IC50 = 13 nM
External Link
TTD: D0WT1Z
 Compound Name N-(2-phenylcyclopropyl) amino acid derivative 2 Patented [9]
Synonyms
PMID27019002-Compound-19a
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 18 nM
External Link
TTD: D0XH9M
 Compound Name PMID27019002-Compound-46 Patented [9]
MOA Inhibitor
External Link
TTD: D0Z7HE
 Compound Name Cyclic peptide derivative 1 Patented [9]
Synonyms
PMID27019002-Compound-compound11
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 5000 nM
External Link
TTD: D04OEV
 Compound Name Heteroaryl-cyclopropylamine derivative 1 Patented [9]
Synonyms
PMID27019002-Compound-22d
    Click to Show/Hide
MOA Inhibitor
Activity EC50 = 8 nM
External Link
TTD: D07NTA
 Compound Name N-(2-phenylcyclopropyl) amino acid derivative 3 Patented [9]
Synonyms
PMID27019002-Compound-19b
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 22 nM
External Link
TTD: D08IOP
 Compound Name N-(2-phenylcyclopropyl) amino acid derivative 1 Patented [9]
Synonyms
PMID27019002-Compound-19
    Click to Show/Hide
MOA Inhibitor
Activity Ki < 1000 nM
External Link
TTD: D0UL9U
 Compound Name Tarnylcypromine derivative 2 Patented [9]
Synonyms
PMID27019002-Compound-26a-h
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1100 to 1900 nM
External Link
TTD: D04OHC
 Compound Name Tarnylcypromine derivative 3 Patented [9]
Synonyms
PMID27019002-Compound-27a-m
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 1300 to 40000 nM
External Link
TTD: D0O7IH
 Compound Name OG-L002 Investigative [11]
Synonyms
1357302-64-7; 4'-((1R,2S)-2-aminocyclopropyl)-[1,1'-biphenyl]-3-ol; SCHEMBL6837351; GTPL7023; OGL002; AOB2070; MolPort-035-395-885; BDBM179446; BCP12278; EX-A2117; s7237; 2610AH; ZINC114026926; AKOS027422749; SB19352; BC600435; 4'-((1R,2S)-2-aminocyclopropyl)biphenyl-3-ol; 3-{4-[(1R,2S)-2-aminocyclopropyl]phenyl}phenol; J-006764; US9676701, 4 4'-((trans)-2-aminocyclopropyl)biphenyl-3-ol hydrochloride
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 20 nM
External Link
CID: 56639570
TTD: D0C8SX
 Compound Name GSK-LSD1 Investigative [12]
Synonyms
GSK-LSD1 2HCl; 1431368-48-7; N-[(1R,2S)-2-phenylcyclopropyl]piperidin-4-amine; GSK LSD1 Dihydrochloride; GTPL8241; SCHEMBL14880683; BDBM256459; 1431368-48-7(free base); ZINC44675892; AKOS030573682; GSK-LSD1, &gt; NCGC00356416-07; US9487512, 3
    Click to Show/Hide
MOA Inhibitor
Activity IC50 = 24 nM
External Link
CID: 71522234
TTD: D0EV7U
 Compound Name NCL-1 Investigative [13]
Synonyms
GTPL7024; ZINC94568752
    Click to Show/Hide
MOA Inhibitor
External Link
CID: 73755256
TTD: D0L6TQ
6C43: Disorders due to use of opioids 1 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name Lofexidine Approved [14]
Synonyms
Britlofex; Lofexidina; Lofexidinum; Britlofex (TN); Lofexidina [INN-Spanish]; Lofexidine (INN); Lofexidine [INN:BAN]; Lofexidinum [INN-Latin]; 1H-Imidazole, 2-(1-(2,6-dichlorophenoxy)ethyl)-4,5-dihydro-(9CI); 2-(1-(2,6-Dichlorophenoxy)ethyl)-4,5-dihydro-1H-imidazole; 2-(a-(2,6-dichlorophenoxy)ethyl)2-imidazoline; 2-(alpha-(2,6-Dichlorophenoxy)ethyl)2-imidazoline; 2-(alpha-(2,6-dichlorophenoxy)ethyl) delta-2-imidazoline; 2-[1-(2,6-dichlorophenoxy)ethyl]-4,5-dihydro-1H-imidazole; 2-{1-[(2,6-dichlorophenyl)oxy]ethyl}-4,5-dihydro-1H-imidazole
    Click to Show/Hide
External Link
CID: 30668
TTD: D0K0MW
DrugBank: DB04948
References
Ref 1 METTL14-mediated upregulation of lncRNA HOTAIR represses PP1alpha expression by promoting H3K4me1 demethylation in oxycodone-treated mice. CNS Neurosci Ther. 2024 Jul;30(7):e14830. doi: 10.1111/cns.14830.
Ref 2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 3 Efficacy of Vafidemstat in Experimental Autoimmune Encephalomyelitis Highlights the KDM1A/RCOR1/HDAC Epigenetic Axis in Multiple Sclerosis. Pharmaceutics. 2022 Jul 6;14(7):1420.
Ref 4 Discovery of CC-90011: A Potent and Selective Reversible Inhibitor of Lysine Specific Demethylase 1 (LSD1). J Med Chem. 2020 Dec 10;63(23):14522-14529.
Ref 5 Clinical pipeline report, company report or official report of Oryzon Genomics Boston, MA
Ref 6 A DNA Hypomethylation Signature Predicts Antitumor Activity of LSD1 Inhibitors in SCLC. Cancer Cell. 2015 Jul 13;28(1):57-69.
Ref 7 Scaffolding LSD1 Inhibitors Impair NK Cell Metabolism and Cytotoxic Function Through Depletion of Glutathione. Front Immunol. 2020 Sep 17;11:2196.
Ref 8 Clinical pipeline report, company report or official report of Astex Pharmaceuticals.
Ref 9 LSD1 inhibitors: a patent review (2010-2015).Expert Opin Ther Pat. 2016 May;26(5):565-80.
Ref 10 Novel monoamine oxidase inhibitors: a patent review (2012 - 2014).Expert Opin Ther Pat. 2015 Jan;25(1):91-110.
Ref 11 A novel selective LSD1/KDM1A inhibitor epigenetically blocks herpes simplex virus lytic replication and reactivation from latency. MBio. 2013 Feb 5;4(1):e00558-12.
Ref 12 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 2669).
Ref 13 Synthesis and biological activity of optically active NCL-1, a lysine-specific demethylase 1 selective inhibitor. Bioorg Med Chem. 2011 Jun 15;19(12):3702-8.
Ref 14 A Phase 3 placebo-controlled, double-blind, multi-site trial of the alpha-2-adrenergic agonist, lofexidine, for opioid withdrawal. Drug Alcohol Depend. 2008 Sep 1;97(1-2):158-68.